Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study

Abstract Purpose Immunotherapy with atezolizumab and bevacizumab is the current first-line standard of care for unresectable hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and efficacy profile of atezolizumab-bevacizumab in the Indian population, as there are limited studies...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Merin Babu, Ashok Sebastian Komaranchath, Arun Valsan, Arun R. Warrier, Rakesh MP, Wesley M. Jose, Nikhil K. Haridas, Sumi Soman, Manjima P. Nair, Shine Sadasivan, Abhinav Menon, Mohammed Thabrez, Keechilat Pavithran
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2025-07-01
Serier:	BMC Cancer
Fag:	atezolizumab bevacizumab hepatocellular carcinoma real world immune checkpoint inhibitors
Online adgang:	https://doi.org/10.1186/s12885-025-14400-9
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!